| Literature DB >> 2838292 |
R Gerritsen van der Hoop1, P de Koning, E Boven, J P Neijt, F G Jennekens, W H Gispen.
Abstract
In rats chronic systemic treatment with cisplatin results in a sensory neuropathy as evidenced by a reduction in the sensory conduction velocity in the sciatic nerve. Concomitant administration of the neurotrophic ACTH4-9 analog, ORG.2766, prevents the occurrence of the neuropathy. In addition, treatment with ORG.2766 stops further deterioration and improves recovery of an already established cisplatin-induced neuropathy. Furthermore, concomitant administration of ORG.2766 during a first cisplatin treatment period results in a better resistance against neurotoxicity in a second exposure period. Finally, ORG.2766 was shown not to hamper the anti-tumor effect of cisplatin in mice, carrying implanted tumor cells from a FMa human tumor line. These data are discussed in view of the potential clinical use of ORG.2766 in prevention and treatment of cisplatin-induced neuropathy.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2838292 DOI： 10.1016/0277-5379(88)90293-3
Source DB: PubMed Journal: Eur J Cancer Clin Oncol ISSN： 0277-5379